Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
9.63
-0.16 (-1.69%)
Jun 8, 2026, 11:41 AM EDT - Market open
Immatics Revenue
Immatics had revenue of 7.61M EUR in the quarter ending March 31, 2026, a decrease of -59.04%. This brings the company's revenue in the last twelve months to 37.30M, down -74.13% year-over-year. In the year 2025, Immatics had annual revenue of 48.27M, down -69.03%.
Revenue (ttm)
37.30M EUR
Revenue Growth
-74.13%
P/S Ratio
30.53
Revenue / Employee
52,457 EUR
Employees
711
Market Cap
1.29B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.27M | -107.57M | -69.03% |
| Dec 31, 2024 | 155.84M | 101.84M | 188.60% |
| Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
| Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
| Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
| Dec 31, 2020 | 31.25M | 12.80M | 69.40% |
| Dec 31, 2019 | 18.45M | 14.68M | 389.36% |
| Dec 31, 2018 | 3.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 427.68M |
| Maravai LifeSciences Holdings | 204.73M |
| UroGen Pharma | 140.49M |
| Precigen | 31.60M |
| Maze Therapeutics | 20.00M |
| Inhibrx Biosciences | 1.30M |
IMTX News
- 7 days ago - Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting - GlobeNewsWire
- 7 days ago - Immatics announces presentation of extended data from Phase 1 trial of IMA401 - TheFly
- 7 days ago - Immatics announces updated Phase 1 data for its Prame TCR T-cell therapy - TheFly
- 8 days ago - Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer - GlobeNewsWire
- 9 days ago - Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting - GlobeNewsWire
- 27 days ago - Immatics reports Q1 EPS (43c), consensus (44c) - TheFly
- 27 days ago - Immatics Announces First Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 27 days ago - Immatics Earnings release: Q1 2026 - Filings